Return to homepagePandemic Pact

Safety and efficacy of the Allocetra-OTS drug

  • Funded by Israel Innovation Authority
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Funder

    Israel Innovation Authority

  • Research Location

    Israel

  • Lead Research Institution

    Enlivex Therapeutics

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Clinical trial (unspecified trial phase)

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Enlivex Therapeutics Ltd. is in the clinical trials stage and is planning to test the safety and efficacy of the Allocetra-OTS drug in COVID-19 patients who are hospitalized in serious to critical condition. Allocetra is an experimental drug which has shown initial promising results in the treatment of patients with multi-system failure related to sepsis, a syndrome with deadly pathology - Cytokine Storm -accompanied by a multi-system failure - similar to the most severe cases of Coronavirus patients.